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ABSTRACT
We studied the value of postgrafting immunosuppression with sirolimus (SRL) and cyclosporine (CSP) in
enhancing engraftment of dog leukocyte antigen–identical littermate marrow after nonmyeloablative condi-
tioning in a canine model. Dogs received either 2 Gy (n7) or 1 Gy (n5) total body irradiation (TBI), followed
by postgrafting immunosuppression with SRL and CSP. In the first cohort, all 7 dogs showed rapid initial
engraftment. One engrafted dog died on day 21 due to hemorrhagic pneumonitis. Durable engraftment was
seen in 5 of 6 remaining dogs, with a median follow-up of >48 (range, >32 to >56) weeks. The sixth dog
rejected the marrow graft (as assessed by variable number of tandem repeats) at 11 weeks; however, a
subsequent skin graft from the same marrow donor did not undergo acute cellular rejection, suggesting
donor-specific tolerance. In the second cohort, all 5 dogs rejected the marrow graft at a median of 9 weeks
(range, 3-11 weeks). We conclude that SRL/CSP is as effective as a previously studied combination of
mycophenolate mofetil and CSP at establishing durable marrow engraftment after sublethal conditioning.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
We have previously reported studies in a canine
model of nonmyeloablative conditioning that achieved
donor marrow engraftment through host immuno-
suppression effected by 2 Gy sublethal total body
irradiation (TBI) given before transplantation and
combined host/donor immunosuppression with my-
cophenolate mofetil (MMF), given for 27 days, and
cyclosporine (CSP), given for 35 days, after transplan-
tation. Graft-host tolerance manifested itself in the
form of stable, mixed donor-host hematopoietic chi-
merism, lasting for years after discontinuation of im-
munosuppression [1]. Here, we evaluated whether
another immunosuppressive agent with a distinct
mechanism of action, sirolimus (SRL), could be sub-
stituted for MMF to achieve engraftment following
sublethal conditioning with TBI.
SRL is a hydrophobic macrocyclic lactone isolated
from Streptomyces hygroscopicus, with a multifaceted
mechanism of immunosuppression that is incom-
pletely understood. Its efﬁcacy as an immunosuppres-
sive agent appears to be primarily based on its anti-
proliferative action, preventing signaling by growth-
promoting lymphokines such as interleukin (IL)-2 and
IL-4. It is not a calcineurin inhibitor despite the fact
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that it binds to the FK506 binding protein (FKBP12).
The FKBP12-SRL complex inhibits the mammalian
target of rapamycin (mTOR, also known as FRAP),
a multifunctional 289-kDa serine-threonine kinase.
mTOR is a key regulator of translation and an integral
component of many signaling pathways. Inhibition
results in disruption of both cytokine-driven pathways
and costimulatory activation, leading to cell-cycle ar-
rest at the G1 phase.
We have previously shown that SRL prolonged sur-
vival of unrelated major histocompatability complex
(MHC)-mismatched marrow recipients who engrafted
after myeloablative conditioning (9.2 Gy TBI), although
results were not superior to other single-drug immuno-
suppressive agents such asmethotrexate (MTX), CSP, or
MMF [2]. SRL has been reported to act in synergy with
CSP and has been used successfully in renal and liver
transplantation [3,4]. Because SRL and CSP have syn-
ergistic immunosuppressive properties [5,6] and differ-
ent side-effect proﬁles, we hypothesized that this com-
bination may be safe and effective in promoting
engraftment after sublethal conditioning.
MATERIALS AND METHODS
Dogs
Litters of beagles and mini-mongrel crossbreeds
were either raised at the Fred Hutchinson Cancer
Research Center (FHCRC), Seattle, WA, or pur-
chased from commercial kennels. Dogs were observed
for disease for at least 60 days before study and were
immunized for distemper, parvovirus, papilloma virus,
leptospirosis, and hepatitis. Research was conducted
according to the principles outlined in the Guide for
Laboratory Animal Facilities and Care prepared by the
National Academy of Sciences, National Research
Council. The Institutional Animal Care and Use
Committee of the FHCRC approved the research
protocols, and the American Association for Accredi-
tation of Laboratory Animal Care certiﬁed the ken-
nels. We selected 12 littermate donor/recipient pairs,
with recipients weighing from 6.6 to 15.2 kg (median,
9.4 kg), which were dog leukocyte antigen (DLA)-
identical by matching for highly polymorphic MHC-
associated class I and class II microsatellite markers
[7,8]. In addition, speciﬁc DLA-DRB1 allelic identity
was conﬁrmed by direct sequencing [9].
Marrow Collection and Infusion. One member of
each littermate pair received marrow following either
2 Gy or 1 Gy TBI administered at 7 cGy/min from a
high-energy linear accelerator (Varian CLINAC 4,
Palo Alto, CA). Marrow was aspirated from donors
under general anesthesia through long needles in-
serted into the humeri. Marrow grafts in the ﬁrst
cohort contained 2.5 to 5.63  108 (median, 4.62 
108) mononuclear cells (MNC) per kilogram, and in
the second cohort contained 3.61 to 6.27  108 (me-
dian, 3.8  108) MNC per kilogram (Table 1). All
dogs received standard postgrafting care. Immunosup-
pression consisted of CSP (15 mg/kg BID p.o. from
day 1 to day 35) combined with SRL (0.05 mg/kg
QD s.c., from day 0 to day 27). CSP assays were
Table 1. Marrow Grafts from DLA-Identical Littermates after Sublethal TBI Delivered at 7 cGy/min
Recipient
No.
MNC
108/kg
GVHD
Rejection
Complete
Autologous
Recovery
Duration
of
ChimerismAcute Chronic
Cohort 1 (2 Gy TBI)
E912 4.27 No Minimal No No >56 weeks
G004 5.62 No No No No >56 weeks
G014 5.35 No No No No >48 weeks
G018 2.63 No No No No >48 weeks
G082 4.55/0.98 No No Yes† Yes 11 weeks*
E214 4.62 No No No No >32 weeks
G132 2.5 No No No No >3 weeks‡
Cohort 2 (1 Gy TBI)
G092 3.61 No No Yes Yes 9 weeks
G111 6.27 No No Yes Yes 11 weeks
G151 3.69 No No Yes Yes 3 weeks
G156 3.80 No No Yes Yes 9 weeks
G167 4.18 No No Yes Yes 9 weeks
SRL 0.05mg/kg QD s.c. on days 0 to 27. CSP 15 mg/kg BID orally on days 1 to 35.
*G082 may have received a suboptimal graft due to delay of 48 hours after harvest prior to transplantation, 4.55 108/kg cells were initially
harvested on day 2. An additional 0.98  108/kg were harvested from the same donor on day 0, and both products were infused on day 0.
†G082 rejected the marrow graft but demonstrated delayed chronic skin graft rejection at 170 days (skin graft from the same marrow
donor).
‡G132 died at 3 weeks of hemorrhagic pneumonitis.
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available for all dogs, and SRL assays became available
at the enrollment of the ﬁfth dog in the ﬁrst cohort.
CSP and SRL levels were measured at least weekly,
with dose adjustments made on the basis of serum
drug levels and clinical toxicity.
Assessment of Chimerism. Hematopoietic engraft-
ment was assessed by documentation of donor dinu-
cleotide and tetranucleotide variable number of tan-
dem repeat (VNTR) polymorphisms in cells from
peripheral blood and marrow using a polymerase
chain reaction (PCR)-based assay as previously de-
scribed [10]. Granulocyte and MNC fractions were
separated from whole blood by gradient centrifuga-
tion using ﬁcoll separation (speciﬁc gravity, 1.074) and
DNA was extracted. PCR ampliﬁcation using infor-
mative radioactively labeled VNTR primers was per-
formed [1]. PCR products were analyzed by gel elec-
trophoresis, and percentages of donor chimerism in
the recipients were determined by visual approxima-
tion after autoradiography.
Reconstitution of SRL. SRL was provided by
Wyeth-Ayerst (Princeton, NJ) as lyophilized powder.
The drug was prepared as a fresh suspension in car-
boxymethylcellulose (CMC) vehicle (0.2 g of CMC
[sodium salt, high viscosity; Sigma C-5013] and
polyoxyethylenesorbitan monooleate [Tween 80,
Sigma P-4780]) dissolved in 100 mL distilled water
and autoclaved. An aliquot of this solution was ho-
mogenized and administered subcutaneously at 0.05
mg/kg within 30 minutes of preparation.
Proliferation Assays of Primary Canine T Cells
Phytohemagglutinin (PHA)-stimulated canine pe-
ripheral blood mononuclear cells were cultured in
quadruplicates for 24 hours at 1  105 cells/well
before adding various concentrations of SRL (Calbio-
chem, San Diego, CA). After 48 hours of culture with
0-100 nmol/L of SRL, cells were pulsed for 16 hours
with 0.5 Ci of 3H-thymidine, harvested, and radio-
activity measured.
RESULTS
SRL Dose-Response Curve
Figure 1 demonstrates the in vitro effect of SRL on
2 primary canine T-cell preparations stimulated with
4 g/mL PHA-M. The proliferation of the T-cell
preparations was suppressed by 80% and 60%, respec-
tively. Maximal inhibition occurred at concentrations
as low as 6 nmol/L SRL, demonstrating potent anti-
proliferative effects on canine T cells.
Engraftment
Cohort 1. Results are summarized in Table 1. All 7
dogs showed rapid initial engraftment. One engrafted
dog (G132) died on day 21 as a result of hemorrhagic
pneumonitis likely secondary to an unusual canine
herpes simplex viral infection, whereas 6 dogs survived
until completion of the study. At the completion of
CSP (5 weeks), median donor granulocyte contribu-
tion was 92% (range, 65%-100%), and median donor
lymphocyte contribution was 45% (range, 40%-70%)
for the 6 evaluable dogs (Figure 2A and 2B). Most
dogs had some reduction in the donor contributions
to chimerism after discontinuation of immunosup-
pression; however, stable, mixed chimerism persisted,
consistent with our prior experience with CSP/MMF.
Durable engraftment was seen in 5 dogs with a median
follow-up of 48 weeks (range, 32 to 56 weeks)
(Table 1). One dog (G082) apparently rejected the
marrow graft (as assessed by VNTR) at 11 weeks and
had complete autologous marrow reconstitution. In
this recipient, infusion of the marrow graft had been
delayed for 48 hours after marrow harvest due to a
technical problem with the linear accelerator. After 24
hours, the harvested marrow (4.55  108 MNC per
kilogram) was cryopreserved using a standard protocol
with dimethylsulfoxide. One day later, the thawed
marrow was infused after TBI was administered. Be-
cause the viability of the graft was of concern, the
cryopreserved marrow was supplemented with a small,
additional quantity (0.98 108 MNC per kilogram) of
fresh marrow cells from the same donor. After appar-
ent rejection of the marrow cell graft, a skin graft from
the marrow donor was transplanted onto G082 in
addition to a DLA-mismatched control skin graft as a
marker of immunocompetence. Historical and con-
current controls suggest that in a normal dog, DLA-
identical skin will undergo acute rejection at a median
of 14 days [11] (unpublished observations), whereas
DLA-mismatched skin grafts are acutely rejected at a
median of 8 to 9 days [12] (unpublished observations).
Extended survival of the marrow donor skin graft
Figure 1. In vitro proliferation of 2 primary canine T-cell prepa-
rations stimulated with 4 g/mL PHA-M. Cells were pulsed for 16
hours with tritiated thymidine (3HTd-R) after 48 hours of culture
with 0-100 nmol/L of SRL. The proliferation of the T-cell prepa-
rations was suppressed by 80% and 60%, respectively. Maximal
inhibition occurred at concentrations as low as 6 nmol/L SRL,
demonstrating potent antiproliferative effects on canine T cells.
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occurred without evidence of acute rejection, whereas
the DLA-mismatched control graft was rejected nor-
mally, suggesting marrow donor-speciﬁc immune tol-
erance. Eventually, evidence of delayed chronic rejec-
tion was detected at 170 days, and this was conﬁrmed
on biopsy. Whether this tolerance was a result of
donor hematopoietic mixed chimerism below the level
of detection by VNTR (2% donor contribution) was
unknown.
Cohort 2. All 5 dogs showed rapid initial engraft-
ment. At the completion of CSP, median donor gran-
ulocyte contribution was 45% (range, 0%-55%), and
median donor lymphocyte contribution was 25%
(range, 0%-50%) (Figure 3A and 3B). Durable en-
graftment was not seen in any of the 5 dogs, and all
bone marrow grafts were rejected 3 to 11 weeks (me-
dian, 9 weeks) after transplantation.
Hematologic Toxicity
Transient neutropenia and lymphopenia were
noted (Figures 2C and 3C). Thrombocytopenia was
occasionally associated with petechiae, but no life-
threatening hemorrhage was noted except for 1 dog
Figure 3. Cohort 2 (1 Gy TBI): Chimerism and hematologic values.
Percent donor peripheral blood granulocytes (A) and lymphocytes
(B) after transplantation in 5 dogs given 100 cGy TBI and DLA-
identical marrow grafts. Results were estimated by visual approxi-
mation of (CA)n dinucleotide repeat marker results. Median hema-
tologic values for 5 dogs (C).
Figure 2. Cohort 1 (2 Gy TBI): Chimerism and hematologic values.
Percent donor peripheral blood granulocytes (A) and lymphocytes
(B) after transplantation in 7 dogs given 200 cGy TBI and DLA-
identical marrow grafts. Results were estimated by visual approxi-
mation of (CA)n dinucleotide repeat marker results. Median hema-
tologic values for 7 dogs (C).
W. J. Hogan et al.
492
(G132), which developed fatal pulmonary hemor-
rhage. Prophylactic transfusions of whole blood or
platelet-rich plasma were considered if the platelet
count fell below 3  109/L or if there was evidence of
widespread petechiae. In cohort 1, 4 of 7 animals
received blood-product support (irradiated whole
blood or platelet-rich plasma), whereas in cohort 2, 2
of 5 animals received prophylactic transfusions. In
comparison, observing historical data from animals
receiving 200 cGy with CSP/MMF, 12 of 17 received
blood-product support, and 0 of 5 animals receiving
100 cGy CSP/MMF received a transfusion.
Nonhematologic Toxicity
Adverse effects associated with the regimen were
predominantly gastrointestinal and generally con-
sisted of anorexia associated with weight loss (range,
3%-31%; median, 11%). One animal, G092, devel-
oped intussusception at 3 weeks’ posttransplantation
coincident with elevated CSP and SRL levels. Intus-
susception is a well-described complication of cal-
cineurin inhibitors in dogs, and successful surgical
correction was possible, allowing this animal to sur-
vive to completion of the study. CSP and SRL are
both metabolized by cytochrome P450 3A4, and ele-
vated levels of both agents were frequently observed in
this study, necessitating dose reductions of both
agents for nearly all animals (Figure 4). Transiently
abnormal liver function tests were noted in some dogs
during the peritransplantation period (Figure 5);
again, these were usually associated with high CSP
levels. One dog (E912) developed transient jaundice
(maximum total bilirubin, 4.2; direct, 2.5 mg/dL),
which resolved within 2 days (total bilirubin, 0.6 mg/
dL). The animal recovered completely and has stable
engraftment more than 1 year later. No signiﬁcant
renal dysfunction was observed in either cohort.
Graft-versus-Host Disease (GVHD)
GVHD was rarely observed, likely explained by
the young age (median, 8.8 months) of the animals
undergoing transplantation. This is equivalent to 3- to
4-year-old human patients, in whom, with proper im-
munosuppression, the incidence of GVHD is also low.
The possibility of GVHD was raised in only 1 animal,
E912, which had a pretransplantation diagnosis of
nonspeciﬁc dermatitis. This animal developed a dif-
fuse skin rash posttransplantation predominantly af-
fecting the ears, and skin biopsy was interpreted as
showing mild GVHD. No evidence of GVHD was
noted in other organs, and the skin rash responded to
symptomatic care.
DISCUSSION
The replacement of myeloablative preparative
regimens by sublethal immunosuppressive condition-
ing followed by intensive, short-term postgrafting im-
munosuppression with a combination of MMF and
CSP represented a major advance in allogeneic hema-
topoietic cell transplantation. The current observa-
tions build on the previous studies, which established
this principle in the canine model. We have demon-
strated that an immunosuppressive agent with a dis-
tinctly different mechanism of action from MMF is
effective at promoting engraftment after sublethal
conditioning. Prior studies suggest that results ob-
tained in this outbred canine model can generally be
reproduced in human trials. It has been observed that
dogs are particularly prone to the toxic effects of SRL
compared with humans, primates, pigs, and mice
[13,14]. Overall, the toxicity of the current regimen
appeared acceptable. One dog died at day 21 from
pulmonary hemorrhage, likely due to an unusual ca-
nine herpes virus infection. All other dogs survived to
Figure 4. Comparison of dose intensity and drug levels for CSP
(n  12) (A) and SRL (n  8) (B). Median doses of CSP and SRL
are represented by bars, with corresponding units on the left vertical
axis, whereas median values for CSP or SRL serum levels are
plotted as points with corresponding units on the right vertical axis.
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completion of the study. The predominant toxicity
was gastrointestinal, with the most serious toxicity
resulting from intussusception, a rare complication in
human patients. No serious cardiac, hepatic, or renal
toxicities were observed. In dogs experiencing graft
rejection, autologous reconstitution occurred without
prolonged cytopenias.
Only 1 animal conditioned with 200 cGy lost
detectable chimerism. The absence of acute cellular
rejection of a subsequent skin graft from the marrow
donor in the presence of normal acute rejection of an
unrelated donor graft suggested unexpected donor-
speciﬁc tolerance. One possible explanation for this
observation was that this animal might have had mixed
chimerism below the detection threshold of 1% to 2%
achieved with the VNTR technique. Interestingly,
another dog from this cohort, G018, had a rapid
decline in the donor contribution after discontinua-
tion of immunosuppression, but subsequently devel-
oped durable, mixed chimerism just above the level of
detection by VNTR. This observation appears to be
consistent with the potential for microchimerism in
this model. Whether microchimerism can lead to do-
nor-speciﬁc tolerance is the subject of signiﬁcant con-
troversy; unfortunately, the recipient was male, pre-
venting more sensitive techniques to detect
microchimerism using real-time PCR with Y chromo-
some–speciﬁc primers.
Although the absence of acute cellular rejection of
a skin graft following apparent rejection of a bone
marrow graft has been observed after other immuno-
suppressive regimens, SRL has a number of intriguing
properties that could be hypothesized to play a role in
immune modulation after marrow transplantation.
Recent reports suggest that SRL may be able to affect
initiation of immune responses at the level of the
dendritic cell. Woltman et al. [15,16] described how
SRL can speciﬁcally induce apoptosis in human den-
dritic cells, but not in other myeloid cells, by interfer-
ing with GM-CSF signaling mediated via the phos-
phatidyl-inositol-3 lipid kinase (PI3K)/mTOR
pathway. SRL also abolishes translation of genes en-
coding proteasome subunit members [17]. The pro-
teasome is essential for the production of peptides for
MHC class I antigen presentation. In addition, there
is evidence to suggest that a functional proteasome is
required for optimal endocytosis of the IL-2 receptor
ligand complex and in the regulation of Jak-STAT
signal transduction including IL-2–induced activation
of STAT5. Inhibition of proteasome activity is also a
common feature of calcineurin inhibitors, providing a
possible ﬁnal common pathway for these immunosup-
pressants [17]. SRL also has mechanisms of action that
are clearly distinct from calcineurin inhibitors and act
at the level of costimulation. Costimulation is required
for functional activation of T cells and can be medi-
ated via the CD28 receptor. Activation of the CD28
receptor has been suggested to have 2 possible com-
ponents: one that is calcium-dependent and sensitive
to CSP; the other calcium-independent and resistant
to CSP. Ghosh et al. reported that SRL could inhibit
the CSP-resistant pathway by interfering with mRNA
stability and translation [18]. The unique spectrum of
immunosuppressive effects produced by SRL implies
that even greater activity may be achieved by combin-
Figure 5. Liver function tests in dogs from both cohorts (n  12).
A, Bilirubin. B, Aspartate transaminase (AST). C, Alkaline phos-
phatase. One dog (E912) developed transient jaundice, possibly as a
result of hemolysis, (maximum total bilirubin, 4.2; direct, 2.5 mg/
dL), which resolved within 2 days (total bilirubin, 0.6 mg/dL). The
animal recovered completely and has stable engraftment more than
1 year later.
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ing it with both a calcineurin inhibitor and an anti-
metabolite.
Another potential strategy to further reduce the
intensity of the pretransplantation conditioning in-
volves transfecting donor hematopoietic cells with
mutant mTOR (mTOR*), which renders the trans-
fected cells resistant to the immunosuppressive action
of SRL. Therefore, it may be possible to provide a
competitive advantage to donor T lymphocytes equiv-
alent to that provided by the pretransplantation ad-
ministration of 200 cGy TBI to the host cells.
In conclusion, we demonstrate that postgrafting
immunosuppression with CSP/SRL can facilitate do-
nor marrow engraftment after sublethal conditioning.
This regimen appears to be superior to CSP/MTX
and produces engraftment rates similar to CSP/MMF.
Because the mechanism of action of the antimetabolite
MMF is very different from SRL, it remains to be
determined whether even greater activity can be
achieved by combining SRL with MMF/CSP. This
question will be addressed in ongoing studies.
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